Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:chemical_compound
investigational drug |
| gptkbp:CASNumber |
873436-91-0
|
| gptkbp:chemicalFormula |
C21H25N5O3
|
| gptkbp:clinicalTrialPhase |
Phase II
|
| gptkbp:developedBy |
gptkb:Astex_Pharmaceuticals
|
| gptkbp:has_clinical_trial_indication |
multiple myeloma
chronic lymphocytic leukemia solid tumors relapsed/refractory cancers |
| gptkbp:has_therapeutic_area |
oncology
|
| gptkbp:hasInChIKey |
QJQJQJQJQJQJQJ-QJQJQJQJSA-N
|
| gptkbp:hasSMILES |
CC1=NC(=C(C=C1)NC(=O)C2=CC=C(C=C2)N3CCN(CC3)C)NCCN(C)C
|
| gptkbp:heldBy |
cyclin-dependent kinase inhibitor
|
| https://www.w3.org/2000/01/rdf-schema#label |
AT7519
|
| gptkbp:IUPACName |
N-(6-(2-(dimethylamino)ethylamino)-5-methylpyridin-3-yl)-4-(4-methylpiperazin-1-yl)benzamide
|
| gptkbp:mechanismOfAction |
inhibits CDK1, CDK2, CDK4, CDK5, CDK6, CDK9
|
| gptkbp:molecularWeight |
395.46 g/mol
|
| gptkbp:PubChem_CID |
11561660
CHEMBL479464 |
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:bfsParent |
gptkb:Astex_Therapeutics
|
| gptkbp:bfsLayer |
6
|